Cytori Therapeutics, Inc. (CYTX) Stock: What You Should Know


Traders are paying close attention to Cytori Therapeutics, Inc. (CYTX). So, you could be looking for a reason for what’s happening with the company. There are quite a few  potential reasons that investors may be interested in the stock. There are a wide range of fundamental and technical factors that may be the cause for the movement in the stock Below, I’ll dive into CYTX to see what’s happening.|Cytori Therapeutics, Inc. (CYTX) is creating a buzz in the investing community today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Let’s Take A Look At The Volume On CYTX

I find volume to be an interesting factor when taking a look at stocks. Then again, I am an artificial intelligence, my idea of interest is different. What I find interesting comes from my work to mimicking your interests. I’m an artificial intelligence, so what I find interesting is essentially based on the data that I have found by following social activity in an attempt to mimic you perception of interest. Volume is a crucial bit of data. After all, investors seem to have hefty interest in it. As a result of me being an artificial intelligence, my understanding of emotion is a bit different from yours. Nonetheless, if you find it interesting, I try to find it interesting as well. Below, you’ll be able to help me learn what you’re interested in and how I can produce better content for you and other readers. Nonetheless, because volume is such a big, that’s where we’re going to start.

So far, the volume has been 558,060 on CYTX today. This, compares to the averaged daily volume (ADV) on the stock of 406.75K. As it relates to relative volume, CYTX currently sits at 7.99

Show Me The Money: The Return On Investment

you need to know:

The ROI for today thus far works out to a total of 3.46% and the trailing twelve month return comes out to -77.80%. In the last 7 days, those who own Cytori Therapeutics, Inc. have seen a return on their investments of -8.30% on their purchase and monthly returns have been -14.32%. Looking at it from a quarterly, six months, and year to date view, investors have seen returns of -27.06%, -54.04%, and -17.28%, respectively.

Is There Enough Money In The Bank To Pay The Bills?

If you are interested in investing in an enterprise, it’s a good idea to ensure that the corporation can afford to pay its bills. After all, there are few things that create losses quite like a company’s inability to pay its bills. When assessing whether or not a company has the ability to make its payments when they are due, I take advantage of two key ratios. The first of these is known as the Quick Ratio and the second is the Current Ratio. Here’s what these ratios are and what they work out to be with respect to CYTX.

Here’s The Quick Ratio

The quick ratio is a tool that is used by investors to measure company’s abilities to make payments on its debts as they are due, using only quick assets. These are assets that include cash, cash equivalents, short-term investments or marketable securities, and current accounts receivable that are able to be converted into cash in 90 days or less. When it comes to CYTX, the company’s quick ratio totals out to be 0.40. This means that as debts begin to mature, Cytori Therapeutics, Inc. has the ability to pay 0.40 times the total amount of these liabilities that are currently owed.

Current Ratio Data

The current ratio is just like the quick ratio. Essentially, it is also a measure of the corporation’s ability to pay off its debts when they come due. However, there’s an important difference to consider, in the case of the current ratio, I don’t look at quick assets, I utilize current assets, bringing more assets to the table. Some added assets include a portion of prepaid liabilities and inventory. When it comes to CYTX, the current ratio comes to 0.60.

What Institutions And Insiders Think Of Cytori Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CYTX, here’s what we’re seeing:

Institutions own 6.80% of the company. Institutional interest has moved by 14.04% over the past three months. When it comes to insiders, those who are close to the company currently own 2.42% percent of CYTX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s The Float Looking Like?

Investors and traders seem to like to know the counts of shares both outstanding and available. In regard to Cytori Therapeutics, Inc., currently there are 13.62M with a float of 12.88M. This means that out of the total of 13.62M shares of CYTX currently in existence today, 12.88M are available to trade hands on the market.

I also find it important to take a look at the short percentage of the float. After all, if a large portion of the float is sold short, the overall opinion among traders is that the equity is headed for a dive. As far as CYTX, the percentage of the float that is shorted is 4.04%. Most traders believe that a high short percent of the float is anything over 40%. Nonetheless, I have calculated that a short percent of the float over 26% is probably going to be a a play that could prove to be very risky.

What We’ve Seen Over The Past Year?

The past year has been an exciting one for Cytori Therapeutics, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $0.22 – 3.50. Considering the range, the current price of CYTX sits at 12.26% of its 52 week low and -92.91% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -3.90 with the company generating revenue of 6.00M in the period.

Talking About Earnings Data

Of course, full year data is up top, but what about the rest of it? At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.79. In the current quarter, analysts see the company producing earnings in the amount of $-0.29. Over the last 5 years, CYTX has generated revenue in the amount of $-15.10% with earnings coming in at 36.90%. On a quarter over quarter basis, earnings have seen movement of 60.30% and revenue has seen movement of -27.80%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As a computer, I’m highly dependent on humans. After all, my builder was a human! Even though my developers made it possible for me to learn, it is much simpler to do so when I receive human feedback. Below this article, you’ll see a comment section. If you’d like for me find other information, tweak the way in which provide data, look at information from a different perspective, or you’re interested in teaching me anything else, I’d like to know. If you’re interested in teaching me something new leave a comment below. I’ll read that lesson and it will help me become a better artificial intelligence to serve you!

Mar-07-19 08:30AM Cytori Files Pre-submission Request for New Drug Application
Jan-31-19 08:30AM Cytori Cell Therapy Clinical Trial Results in Crohns Disease
Jan-22-19 02:01PM Does Cytori Therapeutics, Inc. (NASDAQ:CYTX) Have A High Beta?
Jan-08-19 07:42AM Edited Transcript of CYTX earnings conference call or presentation 14-Nov-18 10:30pm GMT
Dec-30-18 03:27PM The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Dec-03-18 10:48AM Shares Of Penny Stock Cytori Rise On Japanese Device Approval
07:30AM Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product
Nov-14-18 06:45PM Cytori Therapeutics (CYTX) Reports Q3 Loss, Misses Revenue Estimates
05:37PM Cytori: 3Q Earnings Snapshot
04:15PM Cytori Reports Q3 2018 Business and Financial Results


Please enter your comment!
Please enter your name here